Tag: Real-world data
-
Tiger BioSciences Highlights 2025 Clinical Milestones After Bold Research Investment
Overview: A Year of Strategic Investment and Impact In 2025, Tiger BioSciences positioned itself at the forefront of evidence-based biotherapeutics, translating a significant investment in scientific research into tangible clinical milestones. The company’s renewed emphasis on rigorous preclinical validation, translational science, and disciplined trial design aimed to accelerate the journey from discovery to patient impact.…
-
Maternal RSVpreF Vaccination Lowers Infant Hospitalization Risk
Overview: Maternal RSVpreF vaccination and infant protection New real-world evidence is reinforcing the protective effect of maternal vaccination against respiratory syncytial virus (RSV) in early infancy. Data emerging from observational studies suggest that vaccinating pregnant people with the RSV pre-fusion F (RSVpreF) vaccine is associated with a substantial reduction in hospitalizations among young infants, particularly…
-
Nirsevimab Slashes RSV Hospitalizations in US Infants During 2024-2025
Real‑world data show strong protection for US infants A recent research letter analyzing the 2024‑2025 RSV season indicates that administering nirsevimab to infants is associated with fewer hospitalizations due to RSV. While randomized trials proved safety and efficacy, real‑world data confirm that protection extends into everyday clinical practice, easing bed occupancy and the caregiving burden…
-
Nirsevimab Reduces RSV Hospitalizations in US Infants During 2024-25 Season
Overview New real‑world data from the 2024-2025 RSV season indicate that nirsevimab, a monoclonal antibody given to infants to prevent severe respiratory syncytial virus (RSV) infection, provides powerful protection. In a recent research letter analyzing administration patterns and hospitalizations, researchers report a clear reduction in RSV-related hospital stays among U.S. infants who received nirsevimab compared…